[VCYT] Veracyte, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.67 Change: 0.32 (4.35%)
Ext. hours: Change: 0 (0%)

chart VCYT

Refresh chart

Strongest Trends Summary For VCYT

VCYT is in the medium-term up 61% in 3 months and up 53% above S&P in 3 months. In the long-term up 209% above S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 29.28% Sales Growth - Q/Q-8.04% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.05% ROE-86.4% ROI
Current Ratio2.38 Quick Ratio2.12 Long Term Debt/Equity0.25 Debt Ratio0.4
Gross Margin58.11% Operating Margin-71.51% Net Profit Margin-72.28% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities90 K Cash From Investing Activities-440 K Cash From Operating Activities-8.87 M Gross Profit6.65 M
Net Profit-7.61 M Operating Profit-7.55 M Total Assets55.06 M Total Current Assets33.69 M
Total Current Liabilities14.15 M Total Debt4.95 M Total Liabilities19.98 M Total Revenue11.22 M
Technical Data
High 52 week19.69 Low 52 week5.39 Last close19.69 Last change0.05%
RSI55.94 Average true range0.74 Beta1.22 Volume63.83 K
Simple moving average 20 days6.23% Simple moving average 50 days24.11% Simple moving average 200 days66.26%
Performance Data
Performance Week5.86% Performance Month11.81% Performance Quart56.15% Performance Half66.72%
Performance Year246.05% Performance Year-to-date56.52% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.93% Volatility yearly30.92% Relative Volume207.13% Average Volume383.81 K
New High New Low


2019-03-22 09:36:01 | Will Veracyte Continue to Surge Higher?

2019-03-19 07:30:00 | Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition

2019-03-18 07:30:00 | Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019

2019-03-14 13:10:18 | Veracyte, Inc.’s NASDAQ:VCYT Shift From Loss To Profit

2019-03-14 11:15:03 | Veracyte VCYT Reports Q4 Loss, Tops Revenue Estimates

2019-03-05 10:53:03 | Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp

2019-03-04 08:30:00 | Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier

2019-03-04 07:22:12 | 5 Stocks With Recent Price Strength to Maximize Your Gains

2019-02-26 23:45:14 | Edited Transcript of VCYT earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-26 13:52:55 | Veracyte Inc VCYT Q4 2018 Earnings Conference Call Transcript

2019-02-25 16:15:00 | Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook

2019-02-25 15:00:00 | Veracyte Inc to Host Earnings Call

2019-02-25 10:52:35 | Veracyte Q4 Earnings Preview

2019-02-20 16:20:00 | Veracyte Announces Participation in Upcoming Investor Conferences

2019-02-18 10:30:03 | Will Veracyte VCYT Report Negative Earnings Next Week? What You Should Know

2019-02-14 17:54:52 | Veracyte CEO navigated early troubles, now has her company on path to growth

2019-02-06 11:53:46 | Our Take On Veracyte, Inc.’s NASDAQ:VCYT CEO Salary

2019-02-01 07:50:00 | Research Report Identifies Whirlpool, Adtalem Global Education, Reinsurance Group of America, W.R. Berkley, Veracyte, and 22nd Century Group with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-28 16:20:00 | Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019

2019-01-09 16:30:00 | Veracyte to Present at the 21st Annual Needham Growth Conference

2019-01-03 09:54:31 | Can the nose point the way to early lung cancer detection? This Peninsula company's Big Pharma deal aims to find out

2019-01-03 07:00:00 | Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer

2019-01-02 17:54:00 | Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-05 07:30:00 | Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program

2018-11-23 08:55:00 | Investor Expectations to Drive Momentum within Cel-Sci, DGSE Companies, Veracyte, China Pharma, Barnwell Industries, and Silvercrest Asset Management Group — Discovering Underlying Factors of Influence

2018-11-09 08:30:00 | Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

2018-11-08 16:24:00 | Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis

2018-11-01 16:30:02 | Veracyte Raised Its Financial Guidance after Q3 2018

2018-11-01 15:00:02 | A Financial Overview of Veracyte for November

2018-11-01 13:26:13 | Veracyte Stock Witnesses Solid Growth after Its Q3 Results

2018-10-31 12:00:00 | 3 Healthcare Stocks Leading New Industry Trends

2018-10-30 17:27:00 | Here's Why Veracyte Jumped 22.5% Higher Today

2018-10-30 04:04:16 | Edited Transcript of VCYT earnings conference call or presentation 29-Oct-18 8:30pm GMT

2018-10-29 18:10:10 | Veracyte VCYT Reports Q3 Loss, Tops Revenue Estimates

2018-10-29 17:07:31 | Veracyte: 3Q Earnings Snapshot

2018-10-29 16:05:00 | Veracyte Announces Third Quarter 2018 Financial Results

2018-10-29 07:44:08 | Q3 Earnings Preview For Veracyte

2018-10-22 10:31:02 | Veracyte VCYT Q3 Earnings Preview: Here's What to Look Out For

2018-10-15 16:20:00 | Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

2018-10-09 16:05:00 | Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

2018-10-08 16:05:00 | Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

2018-10-06 13:50:00 | Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

2018-10-05 20:38:07 | Versant Venture Management, LLC Buys Veracyte Inc

2018-09-27 16:05:00 | Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-27 08:15:00 | Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018

2018-09-26 08:15:00 | Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

2018-09-10 15:18:27 | Is Veracyte Inc NASDAQ:VCYT A Healthcare Industry Laggard Or Leader?

2018-08-31 08:29:45 | The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

2018-08-30 16:06:00 | Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier

2018-08-30 08:15:00 | Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference